EUVIMEDEUVIMED entdecken
Open Access

Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period

Lorenzo Pelizza iD, Alessandro Di Lisi, Emanuela Leuci, Emanuela Quattrone, Silvia Azzali, Simona Pupo, Giuseppina Paulillo, Pietro Pellegrini, Marco Menchetti

Schizophrenia Bulletin · 2025

DOI: 10.1093/schbul/sbae029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Schizophrenia Bulletin, 2025. Verfasst von Lorenzo Pelizza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum-Università di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Antipsychotic Agents, Psychotic Disorders, Outcome Assessment, Health Care, Schizophrenia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypothesis Antipsychotic (AP) prescription in clinical high risk for psychosis (CHR-P) subjects remains a divisive issue. Although official guidelines currently discourage AP treatment in CHR-P, it is common in clinical practice, especially for psychosis prevention. The aim of this study was to investigate whether baseline AP need (especially in high-dose) indexes a CHR-P subgroup with poorer prognosis and differs from AP-naïve subjects in terms of sociodemographic, clinical, and outcome parameters across a 2-year follow-up. Study Design CHR-P participants were treated within an “Early Intervention in Psychosis” program and completed the Positive and Negative Syndrome Scale (PANSS) and the Global Assessment of Functioning (GAF) scale both at baseline and every 12 months. Individuals with baseline AP prescription were included in the high-dose or low-dose CHR-P-AP+ subgroup. The others were grouped as AP-naïve. Cox regression analyses and mixed-design ANOVA were performed. Study Results 180 CHR-P individuals were enrolled (32 high-dose, 60 low-dose, and 88 AP-naïve). Compared to AP-naive, CHR-P AP+ subgroups showed older age and more severe clinical presentation. High-dose subgroup also had grater functioning decline at entry and poorer functional recovery at follow-up. No inter-group differences in psychosis transition and symptomatic remission were found. Significant improvement in clinical outcomes were found over time in all subgroups. Baseline AP prescription was specifically associated with a more relevant improvement in PANSS total score, and in negative and disorganized symptoms. Conclusions Our results suggest that baseline AP need is an important prognostic parameter in CHR-P and should be considered in risk/benefit calculators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsPsychotic DisordersOutcome Assessment, Health CareSchizophreniaProdromal SymptomsEarly Medical InterventionHumansMaleFemaleAdultFollow-Up StudiesYoung AdultAdolescentRiskPrognosis

Stichwörter der Autor:innen

antipsychoticclinical high riskfollow-upoutcometreatmentultra-high risk

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum-Università di Bologna, Bologna, Italy.
  • Department of Mental Health and Pathological Addiction, Azienda USL di Parma, Parma, Italy.
  • Department of Mental Health and Pathological Addiction, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Pain Therapy Service, Department of Medicine and Surgery, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.

ORCID-Profile: Lorenzo Pelizza

Zitieren

APA

Pelizza, L., Di Lisi, A., Leuci, E., Quattrone, E., Azzali, S., Pupo, S., Paulillo, G., Pellegrini, P., & Menchetti, M. (2025). Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbae029

Vancouver

Pelizza L, Di Lisi A, Leuci E, Quattrone E, Azzali S, Pupo S, et al. Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period. Schizophrenia Bulletin. 2025. doi:10.1093/schbul/sbae029

BibTeX
@article{Pelizza2025,
  author = {Pelizza, Lorenzo and Di Lisi, Alessandro and Leuci, Emanuela and Quattrone, Emanuela and Azzali, Silvia and Pupo, Simona and Paulillo, Giuseppina and Pellegrini, Pietro and Menchetti, Marco},
  title = {Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period},
  journal = {Schizophrenia Bulletin},
  year = {2025},
  doi = {10.1093/schbul/sbae029}
}
Kostenlos starten →